Kura Oncology (NASDAQ:KURA) Shares Cross Above Fifty Day Moving Average of $20.63

Kura Oncology, Inc. (NASDAQ:KURAGet Free Report)’s share price crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $20.63 and traded as high as $21.65. Kura Oncology shares last traded at $21.33, with a volume of 867,490 shares.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of Kura Oncology in a research note on Wednesday, March 6th. JMP Securities boosted their target price on shares of Kura Oncology from $22.00 to $32.00 and gave the stock a “market outperform” rating in a report on Wednesday, January 31st. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Monday, February 12th. Mizuho assumed coverage on shares of Kura Oncology in a research report on Friday, December 22nd. They set a “buy” rating and a $26.00 target price for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $28.28.

View Our Latest Analysis on KURA

Kura Oncology Stock Up 0.8 %

The stock has a market capitalization of $1.62 billion, a PE ratio of -10.25 and a beta of 0.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 12.26 and a quick ratio of 12.26. The business’s fifty day moving average price is $20.63 and its two-hundred day moving average price is $14.09.

Kura Oncology (NASDAQ:KURAGet Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.01. During the same period in the previous year, the firm earned ($0.49) earnings per share. On average, equities research analysts forecast that Kura Oncology, Inc. will post -2.35 EPS for the current fiscal year.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, COO Kathleen Ford sold 1,496 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $26,628.80. Following the sale, the chief operating officer now directly owns 21,602 shares of the company’s stock, valued at approximately $384,515.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, COO Kathleen Ford sold 1,496 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $26,628.80. Following the sale, the chief operating officer now owns 21,602 shares in the company, valued at $384,515.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Thomas James Doyle sold 2,318 shares of Kura Oncology stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $17.80, for a total value of $41,260.40. Following the transaction, the senior vice president now owns 48,093 shares of the company’s stock, valued at $856,055.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 96,919 shares of company stock worth $1,946,415. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of institutional investors have recently modified their holdings of the business. Raymond James & Associates raised its stake in shares of Kura Oncology by 18.6% during the 1st quarter. Raymond James & Associates now owns 17,598 shares of the company’s stock worth $283,000 after buying an additional 2,757 shares during the period. MetLife Investment Management LLC increased its stake in shares of Kura Oncology by 47.3% during the first quarter. MetLife Investment Management LLC now owns 34,950 shares of the company’s stock worth $562,000 after purchasing an additional 11,227 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Kura Oncology by 38.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,070,685 shares of the company’s stock worth $17,217,000 after purchasing an additional 296,175 shares during the last quarter. Vanguard Group Inc. lifted its stake in Kura Oncology by 1.7% in the 1st quarter. Vanguard Group Inc. now owns 3,330,346 shares of the company’s stock valued at $53,553,000 after buying an additional 56,638 shares in the last quarter. Finally, Bridgefront Capital LLC acquired a new stake in Kura Oncology in the 1st quarter worth about $180,000.

About Kura Oncology

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

Further Reading

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.